New Delhi, India
Panacea Biotec, founded in 1994 and headquartered in India, is a prominent player in the Biopharma and Pharmaceutical sector. Known for its commitment to "Innovation in Support of Life," the company has built a robust reputation for research, manufacturing, and marketing of affordable, high-quality pharmaceutical and vaccine products.
With a diverse product portfolio targeting critical therapeutic areas such as pain management, diabetes, cardiovascular, and renal disease management, Panacea Biotec is particularly notable for its advanced vaccine initiatives. Their groundbreaking work in developing the world's first fully liquid Hexavalent and Pentavalent vaccines has positioned them as a leader in the field of disease prevention, specifically in reducing child mortality rates.
In addition to its vaccine innovations, Panacea Biotec has successfully commercialized novel pharmaceutical products like Sitcom, a recognized treatment for hemorrhoids and piles, excelling in several international markets. The company's facilities are compliant with international standards, including WHO Prequalified and US FDA approved certifications, with a distribution reach extending to over 145 countries.
Despite their impressive track record and partnerships with global organizations such as WHO, GAVI, and UNICEF, the company's last investment details remain undisclosed, which could present both an opportunity for fresh capital and a stable growth prospect for potential investors.